Meaghan Granger, MD

Campbell K, Groshen S, Evans AC, Wilson S, Sebastian A, Loots GG, Marachelian A, Armant M, Pal S, Haas-Kogan DA, Park JR, Granger M, Matthay KK, Coleman MA, DuBois SG. Modulation of Radiation Biomarkers in a Randomized Phase II Study of 131I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory Neuroblastoma April 1, 2023 PMID: 36526235 doi: 10.1016/j.ijrobp.2022.11.045

Evans A, Segelke H, Swift A, Wilson P, Vaughan A, Tepper C, Liu S, Davis R, Matthay KK, Granger M, Marachelian A, Haas-Kogan DA, DuBois S and Coleman M. “Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures.” Radiat Res 2022 Feb1; 197(2):101-112. Doi: 10.1667/RADE-20-00173.1 PMID: 34673986

Granger M, Naranjo A, Bagatell R, DuBois SG, McCune JS, Tenney SC, Weiss BD, Mosse YP, Asgharzadeh S, Grupp SA, Hogarty MD, Gastier-Foster JM, Mills D, Shulkin BL, Parisi MT, London WB, Han-Chang J, Panoff J, von Allmen D, Jarzembowski JA, Park JR, Yanik GA. Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Transplant Cell Ther 2021 Jun; 27(6):490.e1-490.e8. doi: 10.1016/j.jtct.2021.03.006. Epub 2021 Mar 6.PMID: 33823167

Mayampurath A, Ramesh S, Michael D, Lui L, Feinberg N, Granger M, Naranjo A, Cohn SL, Volchenboum SL. Applebaum MA. “Predicting Response to Chemotherapy in Patients with Newly Diagnosed High-Risk Neuroblastoma: A Report from the International Neuroblastoma Risk Group. JCO Clin Cancer Inform 2021 Dec; 5 1181-1188 doi: 10.1200/CCI.21.001103 PMID 34882497

Mack JW, Uno H, Twist CJ, Bagatell R, Rosenberg AR, Marachelian A, Granger M, Glade Bender J, Baker JN, Park JR, Cohn SL, Fernandez JH, Diller LR, Shusterman S.J. Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. Pain Symptom Manage 2020 Oct; 60(4):782-789. doi: 10.1016/j.jpainsymman.2020.04.020. Epub 2020 Apr 30. PMID: 32360991 

Mack JW, Cronin AM, Uno H, Shusterman S, Twist C, Bagatell R, Rosenberg A, Marachelian A, Granger M, Glade Bender J, Baker J, Park J, Cohn SL, Levine A, Taddei S and Diller LR. Unrealistic Parental Expectations for Cure in Poor-Prognosis Childhood Cancer. Cancer 2020 Jan 15; 126(2):416-424. doi 10.1002/cncr.32553. Epub 2019 Oct 4 PMID 31584705

Guardia M, Barnes JA, Corey S, Sims J, Granger M. Does Delayed Excretion of Therapeutic 131I-MIBG Interfere with a 123I-MIBG Diagnostic Scan 6 Weeks after the Therapy? Nucl Med Technol 2020 Mar; 48(1):81-84. doi: 10.2967/jnmt.119.229583. Epub 2019 Oct 11. PMID: 31604895 Review.

Mack JW, Cronin AM, Uno H, Shusterman S, Twist C, Bagatell R, Rosenberg A, Marachelian A, Granger M, Glade Bender J, Baker J, Park J, Cohn SL, Levine A, Taddei S and Diller LR. “Unrealistic Parental Expectations for Cure in Poor-Prognosis Childhood Cancer.” Cancer 2020 Jan 15; 126(2):416-424. doi 10.1002/cncr.32553. Epub 2019 Oct 4 PMID 31584705 

Pinto N, Naranjo A, Hibbitts E, Kreissman SG, Granger M, Irwin MS, Bagatell R, London WB, Greengard EG, Park JR, DuBois SG. Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). Eur J Cancer 2019 May; 112:66- 79. doi: 10.1016/j.ejca.2019.02.003. Epub 2019 Apr 1. PMID: 30947024 

Dubois S, Mosse Y, Fox E, Kudgus R, Reid J, McGovern R, Groshen S, Bagatell R, Maris J, Twist C, Goldsmith K, Granger M, Weiss B, Park J, Macy M, Cohn S, Yanik G, Wagner L, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czarnecki S, Luo C, Tsao-Wei D, Matthay K and Marachelian A. Phase 2 Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Journal of Clinical Cancer Research 2018.

Campbell K, Gastier-Foster JM, Mann M, Naranjo AH, Van Ryn C, Bagatell R, Matthay KK, London WB, Irwin MS, Shimada H, Granger M, Hogarty MD, Park JR, DuBois SG. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children’s Oncology Group. Cancer 2017 Jul 11. doi: 10.1002/cncr.30873. [Epub ahead of print] PubMed PMID 28696504

Secola R, Marachelian A, Cohn SL, Toy B, Neville K, Granger M, Brentlinger A, Martin G. The Role of Nursing Professionals in the Management of Patients with High-Risk Neuroblastoma Receiving Dinutuximab Therapy. J Pediatr Oncol Nurs 2017 May/Jun; 34 (3): 160-172. doi: 10.1177/1043454216680595. Epub 2017 Jan 6. PubMed PMID: 28061552

Marachelian A, Villablanca JG, Liu CW, Liu B, Goodarzian F, Lai HA, Shimada H, Tran HC, Parra JA, Gallego R, Bedrossian N, Young S, Czarnecki S, Kennedy R, Weiss BD, Goldsmith K, Granger M, Matthay KK, Groshen S, Asgharzadeh S, Sposto R and Seeger R. Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clin Cancer Res 2017 Sep 15; 23(18): 5374-5383. doi: 10.1158/1078-0432. CCR-16-2647. Epub 2017 May 30. PubMed PMID: 28559462

Padovan-Merhar OM, Raman P, Ostrovnaya I, Kalletla K, Rubnitz KR, Sanford EM, Ali SM, Miller VA, Mosse YP, Granger M, Weiss B, Maris JM, Modak S. “Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.” PLoS Genet 2016 Dec 20; (12): e1006501. doi: 10.1371/journal.pgen.1006501. eCollection 2016 Dec. PubMed PMID: 27997549; PubMed Central PMCID: PMC5172533

DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen E, Giacomini K, Weiss B, Cohn SL, Granger M, Yanik GA, Hawkins R, Courtier J, Jackson H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Villablanca JG, Marachelian A, Matthay KK. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguandine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 2015 Jun 15; 21(12): 2715-21. doi: 10.1158/1078-0432. CCR-14- 3240. Epub 2015 Feb 18. PubMed PMID: 25695691; Pubmed Central PMCID: PMC4470833

De la Guardia M, McCammon S, Nielson K, Granger M. Administration of 131 IMetaiodobenzylguanidine Using the Peristaltic Infusion Pump Method. J Nucl. Med Technol. 2014 Jun; 42(2):109-13. doi: 10.2967/jnmt. 114. 139832. Epub 2014 May 5

French S, DuBois S, Horn B, Granger M, Hawkins R, Pass A, Plummer E, Matthay K. 131I-MIBG followed by Consolidation with Busulfan, Melphalan and Autologous Stem Cell Transplantation for Refractory Neuroblastoma. Pediatric Blood and Cancer 2013 May; 60(5):879-84. doi: 10.1002/pbc.24351. Epub 2012 Sep 28

Granger M, Grupp SA, Kletzel M, Naranjo A, London WB, Diller L. Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting:a Pediatric Oncology Group study: a report from the Children’s Oncology Group. Pediatric Blood Cancer 2012 Nov; 59 (5):902-7. doi: 10.1002/pbc.24207. Epub 2012 Jun 28

Pranzatelli M, Tate ED, Verhulst SJ, Bertalone S, Bhatla D, Granger M, Lebowizc J, Lockhart S, Wiley J, “Pediatric Dosing of Rituximab Revisited: Serum Concentrations in Opsoclonus-Myoclonus Syndrome.” J Pediatr Hematol Oncol 2010 Jul; 32(5): e167-72. doi: 10.1097/MPH. 0b013e3181cf0726